These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17526476)

  • 1. Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder.
    Ilgenli TF; Congologlu A; Ozturk C; Turkbay T; Akpinar O; Kilicaslan F
    Adv Ther; 2007; 24(1):182-8. PubMed ID: 17526476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of metilpheniydate, risperidone and combination therapy on ECG in children with attention-deficit hyperactivity disorder.
    Karpuz D; Hallioglu O; Toros F; Tasdelen B
    J Electrocardiol; 2017; 50(4):410-415. PubMed ID: 28274540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart rate variability and methylphenidate in children with ADHD.
    Buchhorn R; Conzelmann A; Willaschek C; Störk D; Taurines R; Renner TJ
    Atten Defic Hyperact Disord; 2012 Jun; 4(2):85-91. PubMed ID: 22328340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
    Arcieri R; Germinario EA; Bonati M; Masi G; Zuddas A; Vella S; Chiarotti F; Panei P;
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):423-431. PubMed ID: 23362511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of sympathomimetic medication on cardiovascular functioning of children with attention-deficit/hyperactivity disorder.
    Negrao BL; Crafford D; Viljoen M
    Cardiovasc J Afr; 2009; 20(5):296-9. PubMed ID: 19907802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of medications on ventricular repolarization in children with attention deficit hyperactivity disorder.
    Türkmenoğlu YE; Esedova C; Akpinar M; Uysal T; İrdem A
    Int Clin Psychopharmacol; 2020 Mar; 35(2):109-112. PubMed ID: 31633572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Methylphenidate on Ventricular Repolarization Parameters in Children with Attention-Deficit Hyperactivity Disorder.
    Tanır Y; Erbay MF; Özkan S; Özdemir R; Örengül AC
    Alpha Psychiatry; 2023 Sep; 24(5):174-179. PubMed ID: 38105780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship Between Aggravation of Seizures and Methylphenidate Treatment in Subjects with Attention-Deficit/Hyperactivity Disorder and Epilepsy.
    Park J; Choi HW; Yum MS; Ko TS; Shon SH; Kim HW
    J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):537-546. PubMed ID: 30089215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation.
    Stevens JR; George RA; Fusillo S; Stern TA; Wilens TE
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):49-54. PubMed ID: 20166796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.
    Moungnoi P; Maipang P
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S158-63. PubMed ID: 22043770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
    Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
    Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
    Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
    J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.